Amryt Pharma

AMYT: 14.50 -0.25 (-1.69%) delayed: 18 Oct 2018, 7:44

Trade now
Bid Price 14.00 High Price 0.00
Ask Price 15.00 Low Price 0.00
Open Price 0.00 Spread 6.67%
Prev Close 14.75 Volume 0

Amryt Pharma Share Price

Historic - 6 months
>> Advanced Amryt Pharma Charts >>

Amryt Pharma Share Price Information

Name Amryt Pharma
Sector Pharmaceuticals & Biotechnology
Activites Amryt Pharma plc's (formerly Fastnet Equity, formerly Fastnet Oil & Gas plc, formerly Sterling Green Group plc, formerly Hamilton Partners plc) is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments. The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ('bad' cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood. Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis bullosa (EB), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion. Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.
Index n/a
Latest Share Price (p) 14.50 Net Gearing (%) 47.06
Market Capitalisation (£m) 40.54 Gross Gearing (%) 72.67
Shares in issue (m) 274.82 Debt Ratio 68.86
P/E Ratio -1.26 Debt-to-Equity Ratio 0.83
Total dividends per share (p) 0.00 Assets / Equity Ratio 3.66
Dividend Yield (%) 0.00 Price to book value 1.85
Dividend Cover 0.00 ROCE (%) -37.19
Earning per share (p) -11.72 EPS Growth (%) -145.19
52-week high / low (p) 21.88 / 14.75 DPS Growth (%) n/a

Amryt Pharma Broker Views

Date Broker Recommendation Price Old Target Price New Target Price Notes
31 Jan Beaufort Securities Speculative Buy 14.50 - - Reiterates
11 Jan Beaufort Securities Speculative Buy 14.50 - - Reiterates
09 Jan Beaufort Securities Speculative Buy 14.50 - - Reiterates
21 Dec Beaufort Securities Speculative Buy 14.50 65.00 65.00 Reiterates
14 Nov Beaufort Securities Speculative Buy 14.50 65.00 65.00 Reiterates
>> More Amryt Pharma Broker Views >>

Amryt Pharma Director Deals

Date Director Type Volume / Price Trade Value
11 Oct 2017 Harry Stratford Placing 150,000 @ 20.00p £30,000.00
11 Oct 2017 Joe Wiley Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Rory Nealon Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 James Culverwell Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Markus Ziener Placing 132,955 @ 20.00p £26,591.00
>> More Amryt Pharma Director Deals >>

Amryt Pharma News

>> More Amryt Pharma News >>